DVA Stock Analysis: DaVita HealthCare | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 11.730m USD | 12M Return: 40.1% | US23918K1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 124M
EPS Trend: 90.1%
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
DaVita Inc. (NYSE: DVA) is a leading U.S. provider of kidney dialysis services, primarily serving patients with chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates a network of outpatient dialysis centers and provides related lab testing, hospital inpatient services, and home-based hemodialysis. Beyond core dialysis operations, DaVita offers integrated care management, disease management programs, clinical research, physician services, comprehensive kidney care, and a transplant software business. Headquartered in Denver, Colorado, the company was incorporated in 1994 and has been publicly traded since its 1995 IPO.
DaVita operates in the Health Care Services sub-industry, where dialysis is a recurring, high-revenue service driven by chronic, lifelong treatment needs. The U.S. dialysis market is essentially a duopoly, with DaVita and Fresenius Medical Care accounting for the vast majority of outpatient dialysis centers, and a large share of patient treatments is reimbursed through Medicares ESRD entitlement program.
- Medicare reimbursement rate changes pressure dialysis segment margins
- GLP-1 obesity drug adoption may slow long-term ESRD patient growth
- Integrated Kidney Care expansion drives value-based contract revenue
| Net Income: 847.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.72 > 1.0 |
| NWC/Revenue: 9.52% < 20% (prev 8.77%; Δ 0.75% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.19b > Net Income 847.5m |
| Net Debt (12.7b) to EBITDA (2.76b): 4.60 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (66.1m) vs 12m ago -14.57% < -2% |
| Gross Margin: 31.02% > 18% (prev 32.54%; Δ -1.52% > 0.5%) |
| Asset Turnover: 79.59% > 50% (prev 75.24%; Δ 4.36% > 0%) |
| Interest Coverage Ratio: 3.67 > 6 (EBIT TTM 2.05b / Interest Expense TTM 560.1m) |
| A: 0.08 (Total Current Assets 4.19b - Total Current Liabilities 2.86b) / Total Assets 17.7b |
| B: 0.00 (Retained Earnings 81.2m / Total Assets 17.7b) |
| C: 0.12 (EBIT TTM 2.05b / Avg Total Assets 17.6b) |
| D: -0.05 (Book Value of Equity -765.1m / Total Liabilities 16.6b) |
| Altman-Z'' = 1.24 = BB |
| DSRI: 0.95 (Receivables 3.03b/3.00b, Revenue 14.0b/13.2b) |
| GMI: 1.05 (GM 32.54% / 31.02%) |
| AQI: 1.00 (AQ_t 0.47 / AQ_t-1 0.47) |
| SGI: 1.06 (Revenue 14.0b / 13.2b) |
| TATA: -0.08 (NI 847.5m - CFO 2.19b) / TA 17.7b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of September 23, 2026, the stock is trading at USD 183.72 with a total of 529,336 shares traded. Over the past week, the price has changed by -3.76%, over one month by +4.09%, over three months by -12.38% and over the past year by +40.08%.
Current recommended Stop Loss: 176.50 (which is 3.9% or 1.3 ATR below the current price).
DaVita HealthCare has received a consensus analysts rating of 3.10. Therefore, it is recommended to hold DVA.
- StrongBuy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 219.9 | 19.7% |
P/E Trailing = 15.5287
P/E Forward = 9.9404
P/S = 0.8373
P/B = 21.6266
P/EG = 0.448
Revenue TTM = 14.0b USD
EBIT TTM = 2.05b USD
EBITDA TTM = 2.76b USD
Long Term Debt = 10.7b USD (from longTermDebt, last quarter)
Short Term Debt = 117.2m USD (from shortTermDebt, last quarter)
Debt = 13.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.63b
Net Debt = 12.7b USD (calculated: Debt 13.4b - CCE 688.9m)
Enterprise Value = 24.4b USD (11.7b + Debt 13.4b - CCE 688.9m)
Interest Coverage Ratio = 3.67 (Ebit TTM 2.05b / Interest Expense TTM 560.1m)
EV/FCF = 15.19x (Enterprise Value 24.4b / FCF TTM 1.61b)
FCF Yield = 6.58% (FCF TTM 1.61b / Enterprise Value 24.4b)
FCF Margin = 11.49% (FCF TTM 1.61b / Revenue TTM 14.0b)
Net Margin = 6.05% (Net Income TTM 847.5m / Revenue TTM 14.0b)
Gross Margin = 31.02% ((Revenue TTM 14.0b - Cost of Revenue TTM 9.66b) / Revenue TTM)
Gross Margin QoQ = 32.70% (prev 31.42%)
Tobins Q-Ratio = 1.38 (Enterprise Value 24.4b / Total Assets 17.7b)
Interest Expense / Debt = 4.18% (Interest Expense 560.1m / Debt 13.4b)
Taxrate = 20.66% (303.3m / 1.47b)
NOPAT = 1.63b (EBIT 2.05b * (1 - 20.66%))
Current Ratio = 1.47 (Total Current Assets 4.19b / Total Current Liabilities 2.86b)
Debt / Equity = -17.52 (negative equity) (Debt 13.4b / totalStockholderEquity, last quarter -765.1m)
Debt / EBITDA = 4.60 (Net Debt 12.7b / EBITDA 2.76b)
Debt / FCF = 7.90 (Net Debt 12.7b / FCF TTM 1.61b)
Total Stockholder Equity = 291.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.81% (Net Income 847.5m / Total Assets 17.7b)
RoE = 290.7% (Net Income TTM 847.5m / Total Stockholder Equity 291.5m)
RoCE = 18.74% (EBIT 2.05b / Capital Employed (Equity 291.5m + L.T.Debt 10.7b))
RoIC = 11.40% (NOPAT 1.63b / Invested Capital 14.3b)
WACC = 4.80% (E(11.7b)/V(25.1b) * Re(6.49%) + D(13.4b)/V(25.1b) * Rd(4.18%) * (1-Tc(0.21)))
Discount Rate = 6.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -81.87 | Cagr: -13.06%
[DCF] Terminal Value 77.97% ; FCFF base≈1.48b ; Y1≈1.70b ; Y5≈2.50b
[DCF] Fair Price = 390.1 (EV 37.6b - Net Debt 12.7b = Equity 24.9b / Shares 63.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.11 | EPS CAGR: 16.24% | SUE: 0.03 | # QB: 0
Revenue Correlation: 99.77 | Revenue CAGR: 5.90% | SUE: 1.39 | # QB: 3
EPS current Quarter (2026-09-30): EPS=3.58 | Chg30d=+0.00% | Revisions=-67% | Analysts=6
EPS current Year (2026-12-31): EPS=14.85 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+37.7% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=17.25 | Chg30d=+1.38% | Revisions=+0% | GrowthEPS=+16.2% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: -29% (up=6, down=12)